Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Provided By GlobeNewswire
Last update: Mar 11, 2025
Delivered record full-year total revenue and AVISE CTD average selling price
Improved full-year adjusted EBITDA loss and cash use by over 40%
Commercialized new biomarkers to enhance clinical utility of AVISE CTD
NASDAQ:XGN (8/12/2025, 3:00:15 PM)
9.49
+0.11 (+1.17%)
Find more stocks in the Stock Screener
XGN Latest News and Analysis
